Skip to main content

Horn Kinney's Form 4 filing

Olema Pharmaceuticals, Inc. (OLMA) · filed Mar 14, 2022

Accession no.
0001415889-22-002936
Filed
Mar 14, 2022
Trade date
Mar 10, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $25.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Horn KinneyCIK 0001831215Officer (CHIEF BUSINESS OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 10, 2022Common StockMOption exerciseAcquired+5,253$2.06+$10,821.187,711Direct
Mar 10, 2022Common StockSSaleDisposed−5,253$4.75−$24,951.752,458Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 10, 2022Common StockMOption exerciseDisposed−5,253$0.00$0141,785Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)